Background: Macrophage migration inhibitory factor (MIF) is a potent proinflammatory mediator that participates in the pathogenesis of endotoxemia and experimental crescentic glomerulonephritis. However, very little is known about how MIF production is regulated in disease. We therefore examined whether tumor necrosis factor a (TNF-a), a known inducer of MIF expression by macrophages in vitro, up-regulates local and systemic MIT expression in a macrophage-mediated rat model of crescentic glomerulonephritis. Materials and Methods: Anti-glomerular basement membrane (GBM) glomerulonephritis was induced in groups of six primed rats. Animals were treated with 1 mg/kg soluble TNF-a receptor (TNFbp) or saline from the time of disease induction until they were killed on Days 1, 7, or 14. Renal MIF expression was assessed by in situ hybridization, immunohistochemistry, and ELISA, and compared with macrophage accumulation and indices of renal damage. Results: Although TNFbp treatment on Day 1 of the disease had only a partial effect upon the up-regulation
INTRODUCTION
Macrophage migration inhibitory factor (MIF) was originally described as a product of activated T cells that inhibits the migration of macrophages in vitro (1, 2) . Now, however, it is evident that MIF is not exclusively produced by T cells. Recent studies demonstrate that MIF is constitu-tively expressed by a variety of cell types, including monocytes/macrophages, anterior pituitary cells, and renal tubular epithelial cells (3) (4) (5) ). Antibody-blocking studies have shown a key pathogenic role for increased MIF production in experimental endotoxemia (6) . Glucocorticoids at low levels up-regulate MIF expression via a counterregulatory mechanism, whereby MIF can then act to override the glucocorticoid effects (7, 8) . In addition, in vitro studies have shown that the proinflammatory cytokines tumor necrosis factor H. Y. Lan et al.: TNF-aY Upregulates MIF in Glomerulonephritis a (TNF-a) and interferon y (IFN--y) up-regulate macrophage MIF production, and that conversely, MIF induces production of TNF-a and IFN-y (4, 9) , which suggests the presence of an amplifying proinflammatory loop response. However, there is little in vivo evidence for the functional significance of this amplification pathway.
We have recently shown that MIF production is markedly up-regulated in a rat model of crescentic glomerulonephritis. Increased MIF expression correlated significantly with macrophage infiltration, loss of renal function, and development of renal lesions, including glomerular crescent formation (5) . Since TNF-a has been implicated in the pathogenesis of this disease (10,1 1), we sought to determine whether TNF-a is a physiological inducer of MIF production during the disease process. This was examined by blocking the action of TNF-a in rat crescentic glomerulonephritis by treatment with TNF binding protein (TNFbp), a soluble form of recombinant human TNF-a receptor type 1, and by assessing the effect upon MIF expression and renal injury.
MATERIALS AND METHODS

Nephrotoxic Serum
Rabbit anti-rat glomerular basement membrane (GBM) nephrotoxic serum was raised by repeated immunization of New Zealand white rabbits with purified, particulate rat GBM. The sera was pooled, decomplemented at 560C for 30 min, absorbed against rat red blood cells at 40C overnight, and stored at -200C. TNF (17) , which is highly homologous to the rat nucleotide sequence (18) , was used to prepare sense and antisense MIF cRNA probes labeled with digoxigenin-11 -UTP by in vitro transcription according to the manufacturer's protocol (Boehringer Mannheim, Mannheim, Germany). The incorporation of digoxigeninlabeled nucleotides was assayed by spotting serial dilutions of probes onto Hybond nylon membrane (Amersham, Little Chalfont, Buckinghamshire, U.K.) and detecting the bound probe with alkaline phosphatase-conjugated Fab fragments of anti-digoxigenin IgG with 4-nitroblue tetrazolium chloride and X-phosphate substrates according to the manufacturer's instructions (Boehringer Mannheim). Only probes detectable at a concentration of 0.1 pg/,ul or lower were used.
In situ hybridization was performed on 4-gm paraffin sections of formalin-fixed tissue by using a newly developed microwave-based technique (19) . After dewaxing, sections were treated with a microwave oven for 2 X 5 min as outlined above, incubated with 0.2 M HCI for 15 min, followed by 1% Triton X-100 for 15 min, and then digested for 20 min with 10 ,ug/ml proteinase-K at 370C (Boehringer Mannheim). Sections then were washed in 2 X SSC, prehybridized, and then hybridized with 0.3 ng/,ul DIG-labeled sense or anti-sense cRNA probe overnight at 420C in a hybridization buffer containing 50% deionized formamide, 4 X SSC, 2 X Denhardt's solution, 1 mg/ml salmon sperm DNA (Sigma), and 1 mg/ml yeast tRNA. Sections were washed in 0.1 X SSC at 42°C and the hybridized probe detected by means of alkaline phosphatase-conjugated sheep anti-digoxigenin IgG and color development with NBT/X-phosphate. The sections were counterstained with PAS and mounted in an aqueous medium. Some sections were subsequently microwave oven treated and used for three-layer PAP staining with the anti-MIF or ED1 MAb, as described above. Since TNF-a is known to induce macrophage MIF production in vitro, we used double immunohistochemistry staining to examine the number of macrophages expressing MIF mRNA and protein in anti-GBM disease (Fig. 2) . Quantitation of double staining demonstrated that the number of glomerular ED 1 +MIF+ macrophages was significantly inhibited by TNFbp treatment (Fig. 3) . While this was due in part to an overall reduction in the number of glomerular macrophages seen with TNFbp treatment, there was also a reduction in the percentage of glomerular macrophages positive for MIF (25.8 ± 4.5 versus 58.0 ± 3.4% in TNFbp-and saline-treated animals, respectively; p < 0.001).
Quantitation of in Situ Hybridization
Glomerular MIF production was also quantitated by measuring MIF secretion by purified glomeruli during a 24-hr culture period. Substantial levels of MIF were secreted by glomeruli cultured from normal rat kidney (Fig. 4) . This was significantly increased on Day 14 of anti-GBM disease in saline-treated animals. TNFbp treatment caused a significant reduction in glomerular MIF secretion compared with that in saline-treated animals. In addition, TNFbp treatment produced a trend towards a reduction in the basal level of Tubular epithelial cells are the main source of MIF in normal kidney, with up to 30% of cortical tubules being positive for MIF mRNA and protein expression. As in glomeruli, there was a rapid up-regulation in tubular MIF mRNA and protein on Day 1 of saline-treated anti-GBM disease, which was further increased over the course of the disease (Figs. 1 and 2a, c) . A significant interstitial macrophage infiltration occurred in parallel with the increase in MIF expression (Fig. If) . Tubular MIF expression was prominent within focal tubulointerstitial lesions and the development of tubulitis. Double-labeling studies showed that most interstitial ED 1+ macrophages were present in and around tubulointerstitial lesions with strong tubular MIF expression (Fig. 2a, c) .
Consistent with the effects seen in glomeruli, TNFbp treatment caused only a partial reduction in tubular MIF expression on Day 1, but it prevented any further increase in tubular MIF mRNA and protein expression over Days 7 and 14 of the disease (Fig. Id, e) . This was associated with a marked suppression of both interstitial macrophage infiltration and a complete inhibition of tubulointerstitial damage ( These data support the existence of an amplification loop between TNF-a and MIF that exerts a potent proinflammatory effect in vivo. This pathway may operate through the transcription factor NF-KB. Expression of the TNF-a gene is strongly induced by NF-KB, and TNF-a stimulation of target cells results in activation of NF-KB (23, 24) . Furthermore, an NF-KB site has been identified within the promoter of the mouse MIF gene ( 17) . Thus, it is feasible that both TNF-a and MIF act to mutually up-regulate each other through the activation of NF-KB. This may also be the mechanism of the counter-regulatory relationship between MIF and glucocorticoids, since glucocorticoids have recently been shown to exert their anti-inflammatory action by inhibiting activation of NF-KB (25) . Nevertheless, the presence of endocrine-responsive elements within the MIF gene promoter also indicates that the regulation of MIF transcription may be more complex (17) .
In summary, this study has demonstrated that TNF-a-induced up-regulation of local and systemic MIF expression may be one of the important mechanisms mediating renal injury in experimental crescentic glomerulonephritis. Furthermore, this provides the first in vivo evidence that TNF-a and MIF act together in a proinflammatory amplification loop in the pathogenesis of immune/inflammatory disease. cala R. (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J.
